243 related articles for article (PubMed ID: 25753524)
1. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.
Buchner M; Park E; Geng H; Klemm L; Flach J; Passegué E; Schjerven H; Melnick A; Paietta E; Kopanja D; Raychaudhuri P; Müschen M
Nat Commun; 2015 Mar; 6():6471. PubMed ID: 25753524
[TBL] [Abstract][Full Text] [Related]
2. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.
Jiang L; Wang P; Chen L; Chen H
Int J Clin Exp Pathol; 2014; 7(9):5450-60. PubMed ID: 25337187
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Forkhead box protein M1 by thiostrepton increases chemosensitivity to doxorubicin in T-cell acute lymphoblastic leukemia.
Wang JY; Jia XH; Xing HY; Li YJ; Fan WW; Li N; Xie SY
Mol Med Rep; 2015 Jul; 12(1):1457-64. PubMed ID: 25760224
[TBL] [Abstract][Full Text] [Related]
5. Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.
Maekawa A; Kohashi K; Setsu N; Kuda M; Iura K; Ishii T; Matsunobu T; Nakatsura T; Iwamoto Y; Oda Y
Cancer Sci; 2016 Jan; 107(1):95-102. PubMed ID: 26560505
[TBL] [Abstract][Full Text] [Related]
6. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
Uddin S; Hussain AR; Ahmed M; Siddiqui K; Al-Dayel F; Bavi P; Al-Kuraya KS
Haematologica; 2012 Jul; 97(7):1092-100. PubMed ID: 22271891
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy.
Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N
Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794
[TBL] [Abstract][Full Text] [Related]
10. FoxM1 inhibitors as potential anticancer drugs.
Gartel AL
Expert Opin Ther Targets; 2008 Jun; 12(6):663-5. PubMed ID: 18479213
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
12. Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells.
Kuttikrishnan S; Prabhu KS; Khan AQ; Alali FQ; Ahmad A; Uddin S
Leuk Lymphoma; 2021 Dec; 62(13):3170-3180. PubMed ID: 34369229
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs.
Consolaro F; Basso G; Ghaem-Magami S; Lam EW; Viola G
Int J Oncol; 2015 Oct; 47(4):1230-40. PubMed ID: 26316295
[TBL] [Abstract][Full Text] [Related]
14. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
[TBL] [Abstract][Full Text] [Related]
15. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells.
Bhat UG; Halasi M; Gartel AL
PLoS One; 2009; 4(5):e5592. PubMed ID: 19440351
[TBL] [Abstract][Full Text] [Related]
16. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
[TBL] [Abstract][Full Text] [Related]
17. Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line.
Tüfekçi Ö; Yandım MK; Ören H; İrken G; Baran Y
Leuk Res; 2015 Mar; 39(3):342-7. PubMed ID: 25557384
[TBL] [Abstract][Full Text] [Related]
18. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression.
Wang WD; Shang Y; Wang C; Ni J; Wang AM; Li GJ; Su L; Chen SZ
Acta Pharmacol Sin; 2022 Nov; 43(11):2956-2966. PubMed ID: 35422085
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; Polychronis A; Coombes RC; Lam EW
Mol Cancer Ther; 2009 Mar; 8(3):582-91. PubMed ID: 19276163
[TBL] [Abstract][Full Text] [Related]
20. A novel mode of FoxM1 regulation: positive auto-regulatory loop.
Halasi M; Gartel AL
Cell Cycle; 2009 Jun; 8(12):1966-7. PubMed ID: 19411834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
